These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Advances in the chemotherapy of osteosarcoma]. Hu Y; Wang J; Lu S; Zhang B Zhonghua Wai Ke Za Zhi; 1997 Sep; 35(9):571-3. PubMed ID: 10678039 [No Abstract] [Full Text] [Related]
6. [Chemotherapy of osteogenic sarcomas]. Brain E; Jasmin C Chirurgie; 1994-1995; 120(13):193-8. PubMed ID: 8785923 [No Abstract] [Full Text] [Related]
7. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Chou AJ; Gorlick R Expert Rev Anticancer Ther; 2006 Jul; 6(7):1075-85. PubMed ID: 16831079 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Smeland S; Wiebe T; Böhling T; Brosjö O; Jonsson K; Alvegård TA Acta Orthop Scand Suppl; 2004 Apr; 75(311):92-8. PubMed ID: 15188671 [No Abstract] [Full Text] [Related]
9. High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance. Jaffe N; Gorlick R J Clin Oncol; 2008 Sep; 26(27):4365-6. PubMed ID: 18802144 [No Abstract] [Full Text] [Related]
12. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Berger M; Grignani G; Ferrari S; Biasin E; Brach del Prever A; Aliberti S; Saglio F; Aglietta M; Fagioli F Cancer; 2009 Jul; 115(13):2980-7. PubMed ID: 19452540 [TBL] [Abstract][Full Text] [Related]
14. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma. Hundsdoerfer P; Albrecht M; Rühl U; Fengler R; Kulozik AE; Henze G Eur J Cancer; 2009 Sep; 45(14):2447-51. PubMed ID: 19596190 [TBL] [Abstract][Full Text] [Related]
16. Hypocalcemia as a presentation for multifocal osteosarcoma. Soltani A; Hasani-Ranjbar S; Moayyeri A Pediatr Blood Cancer; 2008 Mar; 50(3):687-9. PubMed ID: 17274007 [TBL] [Abstract][Full Text] [Related]
17. The management of osteosarcoma in adults. Souhami RL Clin Oncol (R Coll Radiol); 1990 Mar; 2(2):102-7. PubMed ID: 2261392 [No Abstract] [Full Text] [Related]
18. Use of intra-arterial chemotherapy and embolization before limb salvage surgery for osteosarcoma of the lower extremity. Zhang HJ; Yang JJ; Lu JP; Lai CJ; Sheng J; Li YX; Hao Q; Zhang SM; Gupta S Cardiovasc Intervent Radiol; 2009 Jul; 32(4):672-8. PubMed ID: 19296158 [TBL] [Abstract][Full Text] [Related]
19. Phase II trials of drug combinations: fairytales or fact? Verweij J Eur J Cancer; 2005 Jan; 41(2):195-6. PubMed ID: 15661541 [No Abstract] [Full Text] [Related]
20. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]